Autism

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period. Zygel is cannabidiol formulated in a transdermal gel.  The data were...

Medical cannabis company Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) has just announced the launch of its HOPE line of products for autism in Australia.  The HOPE range of products will be distributed nationally via Health House Holdings. They will be available to Australian patients...

HOPE, a line of medical cannabis tinctures for children and adults with Autism Spectrum Disorder (ASD), is now available in Louisiana cannabis pharmacies and can be sold under prescription. The products — gluten, dairy, soy and nut-free — can be found in all nine of Louisiana...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments. Zynerba said the U.S. Patent and Trademark Office...

Ahora también en Español: Estudio Israelí Apoya al Cannabis como Tratamiento para Síntomas Asociados con el Autismo Israeli researchers have discovered medical cannabis is helpful in alleviating behavioral problems in children with autism. The study conducted by Dr...